c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Tomei, Sara ^a   Mazzanti, Chiara ^a   Marchetti, Ivo ^a   Rossi, Leonardo ^a   Zavaglia, Katia ^a   Lessi, Francesca ^a   Apollo, Alessandro ^a   Aretini, Paolo ^a   Di Coscio, Giancarlo ^a   Bevilacqua, Generoso ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

c kit; Fnac; Thyroid cancer

Indexed keywords

ARTICLE; ASPIRATION BIOPSY; BRAF GENE; C KIT RECEPTOR GENE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE EXPRESSION; GENE SILENCING; GENOTYPE; HUMAN; HUMAN TISSUE; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; MUTATOR GENE; PROTEIN EXPRESSION; PROTO ONCOGENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID NODULE; AMINO ACID SUBSTITUTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NEEDLE BIOPSY; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; THYROID GLAND;

B RAF KINASE; BRAF PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR;

AMINO ACID SUBSTITUTION; BIOPSY, FINE-NEEDLE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; LOGISTIC MODELS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; ROC CURVE; THYROID GLAND; THYROID NODULE;

EID: 84855482946     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-7     Document Type: Article

References (34)

1. Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing?. Ann Surg Oncol 2004, 11:1093-1097. 10.1245/ASO.2004.03.066, 15576834.
2. Miccoli P, Minuto MN, Galleri D, D'Agostino J, Basolo F, Antonangeli L, Aghini-Lombardi F, Berti P. Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease. ANZ J Surg 2006, 76:123-126. 10.1111/j.1445-2197.2006.03667.x, 16626346.
3. Udelsman R, Chen H. The current management of thyroid cancer. Adv Surg 1999, 33:1-27.
4. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993, 328:553-559. 10.1056/NEJM199302253280807, 8426623.
5. Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med 2004, 351:1764-1771. 10.1056/NEJMcp031436, 15496625.
6. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008, 21(Suppl 2):S37-43. 2673022, 18437172.
7. de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 2003, 9:13-19. 10.1007/BF03033708, 12704441.
8. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 2004, 61:2535-2548. 10.1007/s00018-004-4189-6, 15526160.
9. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005, 12:44-56.
10. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006, 30:477-489. 10.1097/00000478-200604000-00008, 16625094.
11. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 2005, 65:8085-8089. 10.1158/0008-5472.CAN-05-0471, 16166280.
12. All-Ericsson C, Girnita L, Muller-Brunotte A, Brodin B, Seregard S, Ostman A, Larsson O. c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?. Invest Ophthalmol Vis Sci 2004, 45:2075-2082. 10.1167/iovs.03-1196, 15223779.
13. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, Bar-Eli M. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 1996, 13:2339-2347.
14. Ko CD, Kim JS, Ko BG, Son BH, Kang HJ, Yoon HS, Cho EY, Gong G, Ahn SH. The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium. Clin Exp Metastasis 2003, 20:593-597. 10.1023/A:1027323210736, 14669790.
15. Tsutsui S, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S. A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer. Br J Cancer 2006, 94:1874-1878. 10.1038/sj.bjc.6603183, 2361342, 16721362.
16. Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Calistri D, Silvestrini R. c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat 2004, 83:33-42. 10.1023/B:BREA.0000010694.35023.9e, 14997053.
17. Natali PG, Berlingieri MT, Nicotra MR, Fusco A, Santoro E, Bigotti A, Vecchio G. Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res 1995, 55:1787-1791.
18. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 2004, 64:2898-2903. 10.1158/0008-5472.CAN-03-3811, 15087409.
19. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res 2008, 14:3327-3337. 10.1158/1078-0432.CCR-07-4495, 3086681, 18519760.
20. Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery 2005, 138:1050-1056. discussion 1056-1057, 10.1016/j.surg.2005.09.010, 16360390.
21. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005, 102:19075-19080. 10.1073/pnas.0509603102, 1323209, 16365291.
22. Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A, Trink B, Mitrani-Rosenbaum S, Roistacher M, Ariel I, Eid A, Freund HR, Nissan A. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 2011, 21:111-118. 10.1089/thy.2010.0356, 21275764.
23. Hamberger B, Gharib H, Melton LJ, Goellner JR, Zinsmeister AR. Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med 1982, 73:381-384. 10.1016/0002-9343(82)90731-8, 7124765.
24. Suen KC. How does one separate cellular follicular lesions of the thyroid by fine-needle aspiration biopsy?. Diagn Cytopathol 1988, 4:78-81. 10.1002/dc.2840040119, 3378490.
25. Caraway NP, Sneige N, Samaan NA. Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases. Diagn Cytopathol 1993, 9:345-350. 10.1002/dc.2840090320, 8519202.
26. Goellner JR. Problems and pitfalls in thyroid cytology. Monogr Pathol 1997, 75-93.
27. Goellner JR, Gharib H, Grant CS, Johnson DA. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol 1987, 31:587-590.
28. Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer 2000, 90:357-363. 10.1002/1097-0142(20001225)90:6<357::AID-CNCR6>3.0.CO;2-4, 11156519.
29. Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio GD, Pinchera A, Bevilacqua G. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid 2009, 19:837-842. 10.1089/thy.2009.0074, 19534623.
30. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007, 28:742-762. 10.1210/er.2007-0007, 17940185.
31. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-1457.
32. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005, 115:1068-1081. 1062891, 15761501.
33. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990, 63:213-224. 10.1016/0092-8674(90)90302-U, 1698556.
34. Jin L, Lloyd RV, Nassar A, Lappinga PJ, Sebo TJ, Swartz K, Seys AR, Erickson-Johnson MR, Roth CW, Evers BR, Oliveira AM, Zhang J. HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR. Diagn Mol Pathol 2011, 20:71-80. 10.1097/PDM.0b013e3181ed784d, 21532495.